CG Oncology announced randomized Phase 3 results for cretostimogene grenadenorepvec in intermediate-risk non-muscle-invasive bladder cancer, reporting a 68% reduction in tumor recurrence risk versus current medical practice. The study enrolled 367 patients, who underwent TURBT and then entered surveillance with repeat procedures only if recurrence occurred. Cretostimogene is administered via catheter into the bladder, where the engineered cold-virus construct targets tumor cells carrying a specific mutation, then replicates and lyses targeted cells to trigger antitumor effects. The company said the data could shift treatment strategies for patients who face repeated resections over time, potentially affecting bladder function. The Phase 3 program and readouts add momentum to intravesical, tumor-targeting immunotherapies, with an explicit focus on durable recurrence control in a setting where recurrence-driven morbidity remains high.